We develop transformative, allogeneic, iPSC-derived NK and T cell therapies to create products for the treatment of both hematological and solid tumor malignancies with significant unmet medical need.

Our engineered, iPSC-derived allogeneic cell therapy platform was designed to yield therapies that overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies.